Investigational drug · Phase 2
VVD-133214
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Adenocarcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VVD-133214"
First trial start
2026
Sep 11, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VVD-133214", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Adenocarcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VVD-133214" as an intervention, largest first.
Vividion Therapeutics, Inc.Industry
NCT06004245 · 280 participants (planned) · Start Jan 25, 2024 · Primary completion May 31, 2027
Drug: VVD-133214; Pembrolizumab and 1 more · For: Advanced Solid Tumors; Colorectal Cancer
Sites: Tucson, Arizona; Duarte, California; Irvine, California · 57 sites in all
- A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumPivotal-lookingRecruiting
Vividion Therapeutics, Inc.Industry
NCT07811193 · 140 participants (planned) · Start Sep 11, 2026 · Primary completion Jun 30, 2028
Drug: VVD-133214; Pembrolizumab · For: Colorectal Adenocarcinoma
Sites: Tucson, Arizona; Ann Arbor, Michigan; Detroit, Michigan · 123 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.
Yap TA, Fontana E, Cook N, et al. · Nat Med 2026
- Structural insights into WRN helicase reveal conformational states and opportunities for MSI-H cancer drug discovery.
Fletcher CT, Mornement AA, Barrett C, et al. · Commun Biol 2026
- Werner helicase as a therapeutic target in mismatch repair deficient colorectal cancer.
Hao S, Liu Z, Lenz HJ, et al. · DNA Repair (Amst) 2025
- Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.
Takemon Y, Pleasance ED, Gagliardi A, et al. · Genome Med 2024
- Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase.
Baltgalvis KA, Lamb KN, Symons KT, et al. · Nature 2024
Also in development for Colorectal Adenocarcinoma
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
- AK129Phase 22 trials
Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
- DKN-01LY2812176Phase 21 trial
Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer
- TST003Phase 21 trial
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.